Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.

Gäckler, Anja; Schönermarck, Ulf; Dobronravov, Vladimir; La Manna, Gaetano; Denker, Andrew; Liu, Peng; Vinogradova, Maria; Yoon, Sung-Soo; Praga, Manuel

Gäckler, Anja; Schönermarck, Ulf; Dobronravov, Vladimir; La Manna, Gaetano; Denker, Andrew; Liu, Peng; Vinogradova, Maria; Yoon, Sung-Soo; Praga, Manuel.

Afiliação

Gäckler A; Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Anja.Gaeckler@uk-essen.de.
Schönermarck U; Medizinische Klinik IV, LMU Klinikum, LMU, Munich, Germany.
Dobronravov V; Pavlov University, Research Institute of Nephrology, St. Petersburg, Russia.
La Manna G; Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, St. Orsola Hospital, University of Bologna, Bologna, Italy.
Denker A; Alexion Pharmaceuticals, Inc., Boston, USA.
Liu P; Alexion Pharmaceuticals, Inc., Boston, USA.
Vinogradova M; National Medical Research Centre for Obstetrics and Gynecology, Moscow, Russia.
Yoon SS; Seoul National University Hospital, Seoul, Republic of Korea.
Praga M; Instituto de Investigación Hospital Universitario 12 de Octubre i+12, Madrid, Spain.

BMC Nephrol ; 22(1): 49, 2021 Feb 02.

Article em En | MEDLINE | ID: mdl-33530925

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article